CTRI/2019/11/022100尚未招募3 期
An 8 week, randomized, double blind, placebo controlled study of the efficacy, safety and tolerability of Sensoril in subjects with mild to moderate, chronic stress
atreon Inc Branch Office India0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age 18 to 60 years, Community dwelling subjects, predominant complaint is anxiety, depression, or sleep disturbances related to chronic stress having Score of 3 or higher on Item 3 of the PSS and Score of 28 or higher on the PSS. This cut off implies an average score of at least 2 for each item. Anxiety, depression, or other symptoms are not a result of exposure to recent, current major life events to which adaptation may occur as a natural event like bereavement or to which adaptation is unlikely cancer or other severe or terminal medical illness. Duration of anxiety, depression, insomnia, or other symptoms related to stress is more than 3 month, this will help to ensure that patients with self limiting stressors are not included, and will help to ensure that patients have failed to cope within 3 months, implying that they will not spontaneously cope, thereafter. Residence within the catchment area of the hospital with reasonable confirmation of feasibility of compliance with study visits. Provision of signed informed consent.
排除标准
- •Anticipation of any change in stressors or life events either increase or decrease, across the course of the study. Any clinically significant medical or psychiatric symptoms for which initiation of medication is indicated, subjects with a DSM 5 diagnosis of Generalized Anxiety Disorder and those with a DSM 5 diagnosis of Dysthymia, however, will be eligible for recruitment provided that their Hamilton Anxiety or HAM-A and Hamilton Depression or HAM-D rating scale scores are each below 18. Any personality disorder, any alcohol or substance use disorder, current smoking 10 or more cigarettes per day will be excluded. Suicidal intent at any time during the past 4 weeks, as determined by self report will be excluded. Use of any psychotropic or nutraceuticals medication for more than 1 week during the past month, use of any psychotropic or nutraceuticals drug during the past week, current treatment with psychotherapy will be excluded.Past history of non-response to Withania somnifera will be excluded. Presence of untreated or unstable major medical comorbidity such as diabetes, hypertension, ischemic heart disease and neuropsychiatric disease, in this context, unstable refers to the occurrence of either a medical incident related to the disease or medication dose adjustment related to the disease during the past month will be excluded. Current or past history of any major medical or neuropsychiatric disorder that may confound the clinical picture of stress and the rating of its severity like mood disorder, psychosis, head injury and stroke will be excluded. If female and of childbearing potential, recruitment will be considered only if the patient is not pregnant, as determined by a pregnancy test, and not lactating, and if an undertaking is provided in the informed consent form that the patient will take sufficient contraceptive or other precautions to avoid conception during the treatment period and for at least one month thereafter, will be excluded.
研究者
相似试验
进行中（未招募）
2 期
The role of resveratrol in the management of metabolic dysregulations in non-alcoholic fatty liver disease: a randomised placebo controlled clinical trialnon-alcoholic fatty liver diseaseMetabolic and Endocrine - Metabolic disordersDiet and Nutrition - ObesityOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12612001135808Metro-South Queensland health20
已完成
不适用
A 8 week, randomized, double-blind, Placebo-controlled clinical trial of extracted Canavalia of complex for the for the for the evaluation of efficacy and safety on immune functioKCT0002757AEKYUNG Industry100
已完成
不适用
A 8 week, randomized, double-blind, Placebo-controlled clinical trial of RB-F for the evaluation of efficacy and safety on immune functioKCT0002646STR Biotech100
已完成
不适用
A 8 week, randomized, double-blind, Placebo-controlled clinical trial of CAEC(Canavalia gladiata Arctium lappa L.(root) Extract Complex) for the evaluation of efficacy and safety on immune functioKCT0003664AEKYUNG Industry100
已完成
不适用
A human trial to evaluate the efficacy and safety of Echinacea extract on promotion of immunity enhancementKCT0006531Wonkwang University. Iksan Korean Medicine Hospital80